OCUL
Ocular Therapeutix, Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom +30.0% · netto nieuwe posities 0.0% · formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 70.61K | $537,539 | n/a | n/a |
| Q2 2026 | 90 | -7 | 115.87M | $1.14B | +4 | −12 |
| Q1 2026 | 101 | +4 | 114.41M | $983.07M | +11 | −8 |
| Q4 2025 | 96 | +1 | 115.21M | $1.40B | +2 | n/a |
| Q3 2025 | 18 | 0 | 82.57M | $965.26M | +1 | −1 |
| Q2 2025 | 15 | +1 | 57.50M | $533.65M | +1 | n/a |
| Q1 2025 | 11 | 0 | 20.34M | $149.08M | +1 | −1 |
| Q4 2024 | 11 | +1 | 19.58M | $167.25M | +2 | −1 |
| Q3 2024 | 9 | +1 | 15.07M | $131.15M | +1 | n/a |
| Q2 2024 | 8 | n/a | 16.30M | $111.49M | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 31.79M | +62.1% | $371.57M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (passief) | 10.56M | +0.1% | $123.41M | 0.0% | ▲ Add | 2 | SEC ↗ ×13 |
| 3 | The Vanguard Group ✦ (passief) | 9.16M | +9.2% | $107.12M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 4 | Citadel Advisors ✦ | 5.70M | +16.7% | $66.68M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 5 | Point72 Asset Management ✦ | 4.60M | +141.6% | $53.79M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 6 | Adage Capital Partners ✦ | 4.00M | +2.9% | $46.81M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 7 | Millennium Management ✦ | 3.86M | +3136.1% | $45.07M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | State Street Global Advisors ✦ (passief) | 3.46M | -1.4% | $40.45M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passief) | 3.34M | +1.6% | $39.03M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Morgan Stanley ✦ | 2.47M | n/a | $28.82M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 11 | Marshall Wace ✦ | 1.60M | Nieuw | $18.72M | 0.0% | New | 1 | SEC ↗ ×3 |
| 12 | Goldman Sachs Group ✦ | 795.97K | n/a | $9.30M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 13 | JPMorgan Chase ✦ | 552.32K | n/a | $6.46M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 14 | Two Sigma Investments ✦ | 234.21K | +111.3% | $2.74M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 145.88K | +31.4% | $1.71M | 0.0% | ▲ Add | 5 | SEC ↗ ×5 |
| 16 | T. Rowe Price ✦ | 131.56K | +4.1% | $1.54M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 113.28K | +10.2% | $1.32M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Wellington Management ✦ | 61.56K | -87.8% | $719,683 | 0.0% | ▼ Trim | 6 | SEC ↗ ×4 |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Marshall Wace | $18.72M | 0.0% |
Verlaten
| Renaissance Technologies | $3.81M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 266 houders, 206.22M aandelen, $1.70B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 11.98K aand · $87,363
Officer · 10.87K aand · $76,626
Officer · 9.99K aand · $70,430
Officer · 3.04K aand · $32,687
Officer · 3.30K aand · $35,531
Officer, Director · 21.65K aand · $233,160
Officer · 1.90K aand · $20,450
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie